These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 31431014)
1. Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor. Azhagiya Singam ER; Tachachartvanich P; La Merrill MA; Smith MT; Durkin KA J Phys Chem B; 2019 Sep; 123(36):7657-7666. PubMed ID: 31431014 [TBL] [Abstract][Full Text] [Related]
2. Conformational dynamics of androgen receptors bound to agonists and antagonists. Gim HJ; Park J; Jung ME; Houk KN Sci Rep; 2021 Aug; 11(1):15887. PubMed ID: 34354111 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation. Liu H; Han R; Li J; Liu H; Zheng L J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066 [TBL] [Abstract][Full Text] [Related]
4. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations. Liu H; An X; Li S; Wang Y; Li J; Liu H Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Osguthorpe DJ; Hagler AT Biochemistry; 2011 May; 50(19):4105-13. PubMed ID: 21466228 [TBL] [Abstract][Full Text] [Related]
6. In silico studies on the molecular interactions of steroid hormones and steroid hormone mimicking drugs in the androgen receptor binding cleft - Implications for prostate cancer treatment. Shimmin BA; Haines LG; Shaw IC Steroids; 2024 Aug; 208():109456. PubMed ID: 38889811 [TBL] [Abstract][Full Text] [Related]
7. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Liu B; Geng G; Lin R; Ren C; Wu JH Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347 [TBL] [Abstract][Full Text] [Related]
8. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression. Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748 [TBL] [Abstract][Full Text] [Related]
9. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells. Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800 [TBL] [Abstract][Full Text] [Related]
10. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen. Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190 [TBL] [Abstract][Full Text] [Related]
11. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Klokk TI; Kurys P; Elbi C; Nagaich AK; Hendarwanto A; Slagsvold T; Chang CY; Hager GL; Saatcioglu F Mol Cell Biol; 2007 Mar; 27(5):1823-43. PubMed ID: 17189428 [TBL] [Abstract][Full Text] [Related]
12. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Hodgson MC; Astapova I; Hollenberg AN; Balk SP Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755 [TBL] [Abstract][Full Text] [Related]
13. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690 [TBL] [Abstract][Full Text] [Related]
14. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Wang LG; Liu XM; Kreis W; Budman DR Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909 [TBL] [Abstract][Full Text] [Related]
15. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033 [TBL] [Abstract][Full Text] [Related]
16. Subtle structural changes in tetrahydroquinolines, a new class of nonsteroidal selective androgen receptor modulators, induce different functions. Nagata N; Kawai K; Nakanishi I J Chem Inf Model; 2012 Aug; 52(8):2257-64. PubMed ID: 22794275 [TBL] [Abstract][Full Text] [Related]
17. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Lu S; Wang A; Lu S; Dong Z Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434 [TBL] [Abstract][Full Text] [Related]
18. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727 [TBL] [Abstract][Full Text] [Related]
19. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei. Karvonen U; Jänne OA; Palvimo JJ FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801 [TBL] [Abstract][Full Text] [Related]
20. The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators. Bogner J; Zolghadr K; Hickson I; Romer T; Yurlova L J Steroid Biochem Mol Biol; 2017 Feb; 166():45-53. PubMed ID: 27174722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]